Physician profile
Douglas G Gresham
NPI 1629155676
$2,972.51
in general payments reported to CMS, 2019-2025
27 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.40 · 2020: $26.59 · 2021: $16.32 · 2022: $318 · 2023: $441 · 2024: $1,114 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.48 |
| Education | $172.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $505.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $449.15 | 2022-2024 | Afrezza |
| Otsuka America Pharmaceutical, INC. | $429.16 | 2024-2025 | Jynarque, Voyxact |
| Insulet Corporation | $224.71 | 2022-2025 | Omnipod |
| Medtronic, INC. | $169.69 | 2022-2025 | Minimed 780g |
| Opko Pharmaceuticals, LLC | $167.47 | 2023-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $141.15 | 2024-2025 | Tarpeyo |
| Vifor Pharma, INC. | $134.69 | 2023-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $120.31 | 2019-2025 | Airsupra, Farxiga |
| Travere Therapeutics, INC. | $108.65 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $102.72 | 2024-2025 | Acthar |
| Averitas Pharma INC. | $69.16 | 2025 | Qutenza |
| Merck Sharp & Dohme LLC | $47.28 | 2021-2023 | Verquvo, Januvia, Steglatro |
| Phathom Pharmaceuticals, INC. | $33.47 | 2024 | Voquezna |
| Ani Pharmaceuticals, INC. | $32.63 | 2024-2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.35 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Cequr Corporation | $25.00 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $24.60 | 2022 | |
| Amgen INC. | $21.32 | 2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $21.31 | 2022 | |
| Aurinia Pharma U.S., INC. | $18.47 | 2024 | Lupkynis |
| Ascensia Diabetes Care US INC. | $18.46 | 2023 | |
| Esperion Therapeutics, INC. | $17.74 | 2024 | Nexletol |
| Tosoh Bioscience, INC. | $17.34 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $13.40 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Gresham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.